• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Cell Mol Med . Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study

tetano

Editor, Senior Moderator
J Cell Mol Med


. 2021 Nov 10.
doi: 10.1111/jcmm.17042. Online ahead of print.
Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study


Guyi Wang[SUP] 1 [/SUP], Shangjie Wu[SUP] 2 [/SUP], Chenfang Wu[SUP] 1 [/SUP], Quan Zhang[SUP] 3 [/SUP], Fang Wu[SUP] 4 [/SUP], Bo Yu[SUP] 1 [/SUP], Siye Zhang[SUP] 1 [/SUP], Chao Wu[SUP] 5 [/SUP], Guobao Wu[SUP] 1 [/SUP], Yanjun Zhong[SUP] 1 [/SUP]



Affiliations

Abstract

This study aims to evaluate the effect of non-alcoholic fatty liver disease (NAFLD) on the susceptibility and consequences of coronavirus disease 2019 (COVID-19). We retrospectively collected data from 218 adult COVID-19 patients who showed no evidence of excessive alcohol consumption and underwent abdominal ultrasound examinations. Of these patients, 39.4% patients had been diagnosed with NAFLD, which indicates a much higher prevalence of NAFLD than that reported in the general population. Significantly elevated white blood cell count (p = 0.008), alanine aminotransferase (p = 0.000), aspartate aminotransferase (p = 0.006) and C reactive protein (p = 0.012) were found in the patients with NAFLD. These patients also had significantly higher proportions of hypertension (p = 0.006) and diabetes (p = 0.049) than the non-NAFLD cases. No significant differences existed in the severity, mortality, viral shedding time and length of hospital stay between patients with or without NAFLD in the sample population. However, subgroup analyses found that in patients with normal body mass index (BMI), NAFLD sufferers were more likely to experience a severe event (30.0% vs 11.5%, p = 0.021). Kaplan-Meier curve (log-rank p = 0.017) and Cox regression (HR = 3.26, 95% CI: 1.17-9.04, p = 0.023) analyses confirmed that before and after adjusting for gender, age and comorbidities, NAFLD patients with normal BMI had a higher incidence of suffering severe events. People with NAFLD may have a higher proportion of COVID-19. NAFLD may be correlated with the severity of COVID-19 patients in the normal BMI group.

Keywords: COVID-19; body mass index; liver injury; non-alcoholic fatty liver disease; outcome; susceptibility.
 
Back
Top Bottom